Novel Platelet Functions in Aging and Venous Thromboembolism (NIH Grant # AG1031065)
An NIH-funded bench-to-bedside investigation studying changes in platelet functions in aging and in patients at risk for venous thromboembolism (IRB_00026265).
ADOPT: Apixaban dosing to optimize protection from thrombosis. A study of medically ill deep vein thrombosis prevention using a novel oral Xa-inhibitor, apixaban (IRB_00024994).
RE-SONATE: Dabigatran etexilate in the long-term prevention of recurrent symptomatic venous thromboembolism in patients who have completed 6-18 months of treatment and are considering discontinuation of anticoagulation (IRB_00025795).
AMPLIFY: A safety and efficacy trial evaluating the use of apixaban in the treatment of symptomatic deep vein thrombosis and pulmonary embolism (IRB_00029133).
AMPLIFY-EXTEND: A safety and efficacy trial evaluating the use of apixaban for the extended treatment of deep vein thrombosis and pulmonary embolism (IRB# 00037618).
BRIDGE: Bridging anticoagulation in patients who require temporary interruption of warfarin therapy for an elective invasive procedure or surgery (IRB_00031805).
ASSERT: Research to better characterize the types of antiphospholipid antibodies (APS) produced in APS, recurrent pregnancy loss (RPL), and VTE and the dominant phospholipid and/or protein epitopes important in each of these disorders (IRB# - pending).
POTENT: Prophylaxis against thromboembolism initiated in the emergency department for high-risk medical patients: A National Quality Improvement Initiative for Hospitals (IRB# 00029071).
GIFT: Genetics Informatics Trial (GIFT) of warfarin therapy to prevent venous thromboembolism s/p joint replacement (IRB# 00036187).
HOKUSAI: Evaluation of efficacy and safety of LMWH heparin/edoxaban vs. LMWH/warfarin in subjects with symptomatic deep vein thrombosis and/or pulmonary embolism (IRB# - pending).
PERMIT: PerMIT: Warfarin: Prospective Randomized Controlled Trial. This is a prospective randomized control trial comparing standard of care vs. PerMIT-guided warfarin management (Personalized Medicine Interface Tool (PerMIT) is a software utility that models dose requirements and response characteristics of individual patients based on their genotypic and physical characteristics) (IRB# 00035279).
Immunologic Mechanisms of Acute Lung Injury (IRB_00028210).
A translational investigation studying genetic influences and gene regulatory pathways on the influence of acute lung injury. This study is funded by a grant from the NIH.
Novel Platelet Functions in Sepsis and Venous Thromboembolism (IRB_00029495).
A translational investigation studying novel platelet functions in patients with sepsis and correlating these activities with the risk of VTE. This study is funded by a grant from the NIH/CCTSA.
